Open AccessBenefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status
Author(s) -
Sarah Pett,
Moira J. Spyer,
Lewis Haddow,
Ruth Nhema,
Laura Benjamin,
Grace Najjuka,
Sithembile Bilima,
Ibrahim I. Daud,
Godfrey Musoro,
Juliet Kitabalwa,
George Selemani,
Salome Kandie,
K Magut Cornelius,
Chrispus Katemba,
J Berkley,
Amin S. Hassan,
Cissy Kityo,
James Hakim,
Robert S. Heyderman,
Diana M. Gibb,
A Sarah Walker,
Reality Trial Team
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002781
Subject(s) - medicine , hazard ratio , cryptococcosis , incidence (geometry) , fluconazole , confidence interval , cumulative incidence , surgery , immunology , cohort , antifungal , dermatology , physics , optics
To assess baseline prevalence of cryptococcal antigen (CrAg) positivity; and its contribution to reductions in all-cause mortality, deaths from cryptococcus and unknown causes, and new cryptococcal disease in the REALITY trial.